Cynosure, Inc. (CYNO) Given Consensus Rating of “Hold” by Brokerages
Cynosure, Inc. (NASDAQ:CYNO) has been assigned an average recommendation of “Hold” from the nine research firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and five have issued a buy recommendation on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $62.00.
Separately, Aegis reissued a “hold” rating and issued a $66.00 price target on shares of Cynosure in a research note on Tuesday, March 28th.
ILLEGAL ACTIVITY WARNING: “Cynosure, Inc. (CYNO) Given Consensus Rating of “Hold” by Brokerages” was first reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/06/23/cynosure-inc-cyno-given-consensus-rating-of-hold-by-brokerages.html.
Shares of Cynosure (CYNO) remained flat at $66.00 during midday trading on Friday. The company’s 50-day moving average is $62.47 and its 200-day moving average is $50.89. Cynosure has a 12 month low of $39.90 and a 12 month high of $66.65.
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Dimensional Fund Advisors LP increased its position in Cynosure by 2.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,216,198 shares of the medical equipment provider’s stock worth $55,459,000 after buying an additional 28,394 shares during the period. State Street Corp increased its stake in shares of Cynosure by 4.8% in the fourth quarter. State Street Corp now owns 601,140 shares of the medical equipment provider’s stock valued at $27,410,000 after buying an additional 27,748 shares during the last quarter. Scout Investments Inc. increased its stake in shares of Cynosure by 25.7% in the first quarter. Scout Investments Inc. now owns 160,275 shares of the medical equipment provider’s stock valued at $7,071,000 after buying an additional 32,750 shares during the last quarter. Teachers Advisors LLC increased its stake in shares of Cynosure by 3.2% in the fourth quarter. Teachers Advisors LLC now owns 38,974 shares of the medical equipment provider’s stock valued at $1,777,000 after buying an additional 1,193 shares during the last quarter. Finally, Guggenheim Capital LLC increased its stake in shares of Cynosure by 7.1% in the fourth quarter. Guggenheim Capital LLC now owns 38,475 shares of the medical equipment provider’s stock valued at $1,755,000 after buying an additional 2,538 shares during the last quarter.
Cynosure Company Profile
Cynosure, Inc develops, manufactures and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve women’s health.
Receive News & Ratings for Cynosure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cynosure Inc. and related companies with MarketBeat.com's FREE daily email newsletter.